DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.

doi:10.1136/jitc-2020-002054

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.

Journal for immunotherapy of cancer - 1 May 2021

Cueto Francisco J, Del Fresno Carlos, Brandi Paola, Combes Alexis J, Hernández-García Elena, Sánchez-Paulete Alfonso R, Enamorado Michel, Bromley Christian P, Gomez Manuel J, Conde-Garrosa Ruth, Mañes Santos, Zelenay Santiago, Melero Ignacio, Iborra Salvador, Krummel Matthew F, Sancho David

Abstract excerpt

BACKGROUND: Conventional type 1 dendritic cells (cDC1s) are central to antitumor immunity and their presence in the tumor microenvironment associates with improved outcomes in patients with cancer. DNGR-1 (CLEC9A) is a dead cell-sensing receptor highly restricted to cDC1s. DNGR-1 has been involved in both cross-presentation of dead cell-associated antigens and processes of disease tolerance, but its role in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Basic-Leucine Zipper Transcription Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemokine CCL5

Share to Lectins, C-Type

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma, Experimental

Share to Receptors, CCR5

Share to Tumor Burden

Share to Tumor Escape

Source

Open in PubMed Open full text

Identifiers

PMID: 33980589
DOI: 10.1136/jitc-2020-002054
PMCID: PMC8118081

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.PMID 33980589Read ↗

A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunitySemantic proximity Read ↗

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.Semantic proximity Read ↗

An NF-κB/IRF1 axis programs cDC1s to drive anti-tumor immunitySemantic proximity Read ↗

Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity.Semantic proximity Read ↗

CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumorsSemantic proximity Read ↗

PD-1 blockade-driven anti-tumor CD8 <sup>+</sup> T cell immunity requires XCR1 <sup>+</sup> dendritic cellsSemantic proximity Read ↗

KLRG1 identifies circulating cytotoxic CD4 T cells with selective anti-tumor function in human cancerSemantic proximity Read ↗

Pan-cancer mapping of single T cell profiles reveals a TCF1:CXCR6-CXCL16 regulatory axis essential for effective anti-tumor immunitySemantic proximity Read ↗

Conventional dendritic cells type I with an enhanced type-I-IFN signaling underpin anti-tumor immune responses in brain metastasesSemantic proximity Read ↗

STING Licensing of Type I Dendritic Cells Potentiates Antitumor ImmunitySemantic proximity Read ↗

CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environmentSemantic proximity Read ↗

Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.